Cellular mechanisms for diastolic dysfunction in the human heart

Dániel Czuriga, Walter J. Paulus, I. Czuriga, I. Édes, Z. Papp, A. Borbély

Research output: Contribution to journalArticle

10 Citations (Scopus)

Abstract

Left ventricular (LV) diastolic dysfunction is an important contributor to many different cardiovascular diseases. LV diastolic dysfunction can manifest itself as slow LV relaxation, slow LV filling or high diastolic LV stiffness. Diastolic abnormalities have been described in the senescent heart, in heart failure with preserved ejection fraction (HFPEF), in diabetic cardiomyopathy, in aortic valve stenosis (AVS), in hypertrophic cardiomyopathy (HCM), as well as in Fabry disease (FD), however, exact cellular and molecular alterations behind the diastolic deterioration in these diseases are not yet completely characterized. Several studies thoroughly investigated altered cardiomyocyte function, changes of contractile myofilaments, extracellular collagen deposition and advanced glycation end products (AGEs) cross-linking in the background of diastolic dysfunction. These clinical and experimental data suggest that underlying mechanisms of LV diastolic dysfunction are divergent in different cardiac pathologies, therefore the present review aims to summarize mechanisms at the cellular level of diastolic abnormalities in various cardiovascular diseases.

Original languageEnglish
Pages (from-to)2532-2538
Number of pages7
JournalCurrent Pharmaceutical Biotechnology
Volume13
Issue number13
DOIs
Publication statusPublished - 2012

Fingerprint

Left Ventricular Dysfunction
Cardiovascular Diseases
Diabetic Cardiomyopathies
Fabry Disease
Advanced Glycosylation End Products
Myofibrils
Hypertrophic Cardiomyopathy
Aortic Valve Stenosis
Cardiac Myocytes
Collagen
Heart Failure
Pathology

Keywords

  • Cardiomyocytes
  • Contractile dysfunction
  • Diabetes mellitus
  • Diastole
  • Fibrosis
  • Human heart

ASJC Scopus subject areas

  • Pharmaceutical Science
  • Biotechnology

Cite this

Cellular mechanisms for diastolic dysfunction in the human heart. / Czuriga, Dániel; Paulus, Walter J.; Czuriga, I.; Édes, I.; Papp, Z.; Borbély, A.

In: Current Pharmaceutical Biotechnology, Vol. 13, No. 13, 2012, p. 2532-2538.

Research output: Contribution to journalArticle

@article{1530d516c71a497291d645b3d488149a,
title = "Cellular mechanisms for diastolic dysfunction in the human heart",
abstract = "Left ventricular (LV) diastolic dysfunction is an important contributor to many different cardiovascular diseases. LV diastolic dysfunction can manifest itself as slow LV relaxation, slow LV filling or high diastolic LV stiffness. Diastolic abnormalities have been described in the senescent heart, in heart failure with preserved ejection fraction (HFPEF), in diabetic cardiomyopathy, in aortic valve stenosis (AVS), in hypertrophic cardiomyopathy (HCM), as well as in Fabry disease (FD), however, exact cellular and molecular alterations behind the diastolic deterioration in these diseases are not yet completely characterized. Several studies thoroughly investigated altered cardiomyocyte function, changes of contractile myofilaments, extracellular collagen deposition and advanced glycation end products (AGEs) cross-linking in the background of diastolic dysfunction. These clinical and experimental data suggest that underlying mechanisms of LV diastolic dysfunction are divergent in different cardiac pathologies, therefore the present review aims to summarize mechanisms at the cellular level of diastolic abnormalities in various cardiovascular diseases.",
keywords = "Cardiomyocytes, Contractile dysfunction, Diabetes mellitus, Diastole, Fibrosis, Human heart",
author = "D{\'a}niel Czuriga and Paulus, {Walter J.} and I. Czuriga and I. {\'E}des and Z. Papp and A. Borb{\'e}ly",
year = "2012",
doi = "10.2174/138920112804583005",
language = "English",
volume = "13",
pages = "2532--2538",
journal = "Current Pharmaceutical Biotechnology",
issn = "1389-2010",
publisher = "Bentham Science Publishers B.V.",
number = "13",

}

TY - JOUR

T1 - Cellular mechanisms for diastolic dysfunction in the human heart

AU - Czuriga, Dániel

AU - Paulus, Walter J.

AU - Czuriga, I.

AU - Édes, I.

AU - Papp, Z.

AU - Borbély, A.

PY - 2012

Y1 - 2012

N2 - Left ventricular (LV) diastolic dysfunction is an important contributor to many different cardiovascular diseases. LV diastolic dysfunction can manifest itself as slow LV relaxation, slow LV filling or high diastolic LV stiffness. Diastolic abnormalities have been described in the senescent heart, in heart failure with preserved ejection fraction (HFPEF), in diabetic cardiomyopathy, in aortic valve stenosis (AVS), in hypertrophic cardiomyopathy (HCM), as well as in Fabry disease (FD), however, exact cellular and molecular alterations behind the diastolic deterioration in these diseases are not yet completely characterized. Several studies thoroughly investigated altered cardiomyocyte function, changes of contractile myofilaments, extracellular collagen deposition and advanced glycation end products (AGEs) cross-linking in the background of diastolic dysfunction. These clinical and experimental data suggest that underlying mechanisms of LV diastolic dysfunction are divergent in different cardiac pathologies, therefore the present review aims to summarize mechanisms at the cellular level of diastolic abnormalities in various cardiovascular diseases.

AB - Left ventricular (LV) diastolic dysfunction is an important contributor to many different cardiovascular diseases. LV diastolic dysfunction can manifest itself as slow LV relaxation, slow LV filling or high diastolic LV stiffness. Diastolic abnormalities have been described in the senescent heart, in heart failure with preserved ejection fraction (HFPEF), in diabetic cardiomyopathy, in aortic valve stenosis (AVS), in hypertrophic cardiomyopathy (HCM), as well as in Fabry disease (FD), however, exact cellular and molecular alterations behind the diastolic deterioration in these diseases are not yet completely characterized. Several studies thoroughly investigated altered cardiomyocyte function, changes of contractile myofilaments, extracellular collagen deposition and advanced glycation end products (AGEs) cross-linking in the background of diastolic dysfunction. These clinical and experimental data suggest that underlying mechanisms of LV diastolic dysfunction are divergent in different cardiac pathologies, therefore the present review aims to summarize mechanisms at the cellular level of diastolic abnormalities in various cardiovascular diseases.

KW - Cardiomyocytes

KW - Contractile dysfunction

KW - Diabetes mellitus

KW - Diastole

KW - Fibrosis

KW - Human heart

UR - http://www.scopus.com/inward/record.url?scp=84871462659&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84871462659&partnerID=8YFLogxK

U2 - 10.2174/138920112804583005

DO - 10.2174/138920112804583005

M3 - Article

VL - 13

SP - 2532

EP - 2538

JO - Current Pharmaceutical Biotechnology

JF - Current Pharmaceutical Biotechnology

SN - 1389-2010

IS - 13

ER -